My reservation is that RVNC isn't getting enough early (i.e. up-front + clinical-milestones) cash for a deal of this nature.
As things stand (following the MYL deal), RVNC might be able to get to the US launch of RT002 without raising additional capital, but they would be cutting it close.
p.s. I don't think MYL could have developed a Botox biosimilar on its own.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.